Y-mAbs Therapeutics Reports Positive Quarterly Results Surpassing Analysts' Projections

Thursday, 29 February 2024, 21:24

Y-mAbs Therapeutics has announced their quarterly results, showcasing a remarkable performance that exceeded market expectations. Despite a negative GAAP EPS of -$0.02, the company beat estimates by $0.18. Furthermore, their revenue of $23.4M surpassed projections by $2.45M, indicating a robust financial performance.
LivaRava Finance Meta Image
Y-mAbs Therapeutics Reports Positive Quarterly Results Surpassing Analysts' Projections

Y-mAbs Therapeutics Financial Results

Y-mAbs Therapeutics announced their latest quarterly results, revealing impressive figures.

Key Highlights:

  • GAAP EPS: Y-mAbs reported a negative EPS of -$0.02.
  • Revenue: The company generated $23.4M in revenue.
  • Beating Estimates: Y-mAbs surpassed market expectations by $0.18 in EPS and $2.45M in revenue.

The financial performance of Y-mAbs Therapeutics has garnered attention for its strength and outperformance.


This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.


Related posts


Newsletter

Get the most reliable and up-to-date financial news with our curated selections. Subscribe to our newsletter for convenient access and enhance your analytical work effortlessly.

Subscribe